Veronika Bahlinger

PUBLICATIONS
First or last authorships
Bahlinger V, Hartmann A, Eckstein M. Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors. Advances in anatomic pathology. 2022. IF: 4,571
Weyerer V, Stoehr R, Bertz S, Lange F, Geppert CI, Wach S, Taubert H, Sikic D, Wullich B, Hartmann A, Eckstein M. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J Urol. 2021;39(11):4011-9. IF: 4,226
Kullmann F, Strissel PL, Strick R, Stoehr R, Eckstein M, Bertz S, Wullich B, Sikic D, Wach S, Taubert H, Olbert P, Heers H, Lara MF, Macias ML, Matas-Rico E, Lozano MJ, Prieto D, Hierro I, van Doeveren T, Bieche I, Masliah-Planchon J, Beaurepere R, Boormans JL, Allory Y, Herrera-Imbroda B, Hartmann A, Weyerer V. Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. Journal of clinical pathology. 2023;76(2):126-32. IF: 4,467
Weyerer V, Strissel PL, Strick R, Sikic D, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Breyer J, Bolenz, C, Erben P, Schmitz-Draeger B, Wullich B, Harmtann A, Eckstein M. Integration of spatial PD-L1 expression with the tumor immune microenvironment outperforms standard PD-L1 scoring in outcome prediction of urothelial cancer patients. Cancers 202. IF: 6,126
Weyerer V, Strissel PL, Stohr C, Eckstein M, Wach S, Taubert H, Brandl L, Geppert CI, Wullich B, Cynis H, Beckmann MW, Seliger B, Hartmann A, Strick R. Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. Front Oncol. 2021;11:657187. IF: 5,085
Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, Togel L, Geppert CI, Sikic D, Taubert H, Wach S, Wullich B, Hartmann A, Stoehr R, Giedl J. TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. Genes (Basel). 2021;12(2). IF: 2,984
Weyerer V, Eckstein M, Comperat E, Juette H, Gaisa NT, Allory Y, Stohr R, Wullich B, Roupret M, Hartmann A, Bertz S. Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. Cancers (Basel). 2020;12(3). IF: 6,126
Weyerer V*, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Comperat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology. 2019;75(6):865-75. IF: 3,626
Zinnall U, Weyerer V*, Comperat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Hum Pathol. 2018;80:55-64. IF: 2,904
Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Ruschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J. Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer. 2017;8(3):323-31. IF: 3,182
* Shared first co-authorship
Co-authorships
Erlmeier F, Klumper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Holzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. European urology. 2023;83(2):133-42. IF: 20,096
Diez S, Renner M, Bahlinger V, Hartmann A, Besendorfer M, Muller H. Increased expression of OLFM4 and lysozyme during necrotizing enterocolitis in neonates: an observational research study. BMC Pediatr. 2022;22(1):192. IF: 2,438
Kohler SA, Brandl L, Strissel PL, Glossner L, Ekici AB, Angeloni M, Ferrazzi F, Bahlinger V, Hartmann A, Beckmann MW, Eckstein M, Strick R. Improved Bladder Tumor RNA Isolation
from Archived Tissues Using Methylene Blue for Normalization, Multiplex RNA Hybridization, Sequencing and Subtyping. Int J Mol Sci. 2022;23(18). IF: 6,208
Sikic D, Weyerer V, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Schmitz-Draeger BJ, Wullich B, Hartmann A, Eckstein M. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. Urologic oncology. 2022;40(2):63 e19-63 e26. IF: 3,498
Diez S, Besendorfer M, Weyerer V, Hartmann A, Moosmann J, Weiss C, Renner M, Muller H. DMBT1 expression and neutrophil-to-lymphocyte ratio during necrotizing enterocolitis are influenced by impaired perfusion due to cardiac anomalies. Mol Cell Pediatr. 2022;9(1):1. IF: 1,184
Tully KH, Jutte H, Wirtz RM, Jarczyk J, Santiago-Walker A, Zengerling F, Breyer J, Sikic D, Kriegmair MC, von Hardenberg J, Wullich B, Taubert H, Weyerer V, Stoehr R, Bolenz C, Burger M, Porubsky S, Hartmann A, Roghmann F, Erben P, Eckstein M. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology. 2021;157:93-101. IF: 2,649
Eckstein M, Lieb V, Jung R, Sikic D, Weigelt K, Stohr R, Geppert C, Weyerer V, Bertz S, Serrero G, Yue B, Hartmann A, Wullich B, Taubert H, Wach S. Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients. Cells. 2021;10(7). IF: 7,677
Sikic D, Eckstein M, Weyerer V, Kubon J, Breyer J, Roghmann F, Kunath F, Keck B, Erben P, Hartmann A, Wirtz RM, Wullich B, Taubert H, Wach S. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. Urologic oncology. 2022;40(2):63 e9- e18. IF: 3,498
Sikic D, Taubert H, Wirtz RM, Breyer J, Eckstein M, Weyerer V, Kubon J, Erben P, Bolenz C, Burger M, Hartmann A, Wullich B, Wach S, Keck B. High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. Life (Basel). 2021;11(7). IF: 3,251
Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat S, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in anatomic pathology. 2021;28(4):179-95. IF: 4,571
Sikic D, Weyerer V, Geppert CI, Bertz S, Lange F, Taubert H, Wach S, Schmitz-Draeger BJ, Wullich B, Hartmann A, Eckstein M. Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy. Urologic oncology. 2022;40(2):63 e19-63 e26. IF: 3,498
Diez S, Besendorfer M, Weyerer V, Hartmann A, Moosmann J, Weiss C, Renner M, Muller H. DMBT1 expression and neutrophil-to-lymphocyte ratio during necrotizing enterocolitis are influenced by impaired perfusion due to cardiac anomalies. Mol Cell Pediatr. 2022;9(1):1.
Jutte H, Reike M, Wirtz RM, Kriegmair M, Erben P, Tully K, Weyerer V, Eckstein M, Hartmann A, Eidt S, Wezel F, Bolenz C, Tannapfel A, Noldus J, Roghmann F. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant
Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. J Pers Med. 2021;11(6). IF: 3,368
Sikic D, Taubert H, Breyer J, Eckstein M, Weyerer V, Keck B, Kubon J, Otto W, Worst TS, Kriegmair MC, Erben P, Hartmann A, Wullich B, Wirtz RM, Wach S. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. Cancer Manag Res. 2021;13:6567-78. IF: 3,989
Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S, Wullich B, Bertz S, Weyerer V, Stoehr R, Breyer J, Burger M, Hartmann A, Strissel PL, Eckstein M. Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling. Cancer Res. 2021;81(6):1552-66. IF: 9,130
Taubert H, Eckstein M, Epple E, Jung R, Weigelt K, Lieb V, Sikic D, Stohr R, Geppert C, Weyerer V, Bertz S, Kehlen A, Hartmann A, Wullich B, Wach S. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy. Cells. 2021;10(1). IF: 4,366
Schmiester M, Dolnik A, Kornak U, Pfitzner B, Hummel M, Treue D, Hartmann A, Agaimy A, Weyerer V, Lekaj A, Brakemeier S, Peters R, Ollinger R, Mardian S, Bullinger L, Striefler JK, Florcken A. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms. J Pathol Clin Res. 2021;7(1):3-9. IF: 3,489
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtroder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjodahl G, Hoglund M, Steiniche T, Mogensen K, de Reynies A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmstrom PU, Malats N, Real FX, Dyrskjot L. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12(1):2301. IF: 12,121
Sikic D, Eckstein M, Wirtz RM, Jarczyk J, Worst TS, Porubsky S, Keck B, Kunath F, Weyerer V, Breyer J, Otto W, Rinaldetti S, Bolenz C, Hartmann A, Wullich B, Erben P. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. J Clin Med. 2020;9(4). IF: 1,883
Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knuchel R, Vogeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT, German Study Group of Bladder C. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer. 2020;20(1):230. IF: 3,150
Maisch S, Mueller SK, Traxdorf M, Weyerer V, Stoehr R, Iro H, Hartmann A, Agaimy A. Sinonasal papillomas: A single centre experience on 137 cases with emphasis on malignant transformation and EGFR/KRAS status in "carcinoma ex papilloma". Ann Diagn Pathol. 2020;46:151504. IF: 1,877
Kubon J, Sikic D, Eckstein M, Weyerer V, Stohr R, Neumann A, Keck B, Wullich B, Hartmann A, Wirtz RM, Taubert H, Wach S. Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis. Cancers (Basel). 2020;12(10). IF: 6,126
Herrmann H, Cabet E, Chevalier NR, Moosmann J, Schultheis D, Haas J, Schowalter M, Berwanger C, Weyerer V, Agaimy A, Meder B, Muller OJ, Katus HA, Schlotzer-Schrehardt U, Vicart P, Ferreiro A, Dittrich S, Clemen CS, Lilienbaum A, Schroder R. Dual Functional States of R406W-Desmin Assembly Complexes Cause Cardiomyopathy With Severe Intercalated Disc Derangement in Humans and in Knock-In Mice. Circulation. 2020;142(22):2155-71. IF: 23,603
Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W, Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D, Bridge Consortium e.V MG. Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer. 2020;8(1). IF: 10,252
Eckstein M, Epple E, Jung R, Weigelt K, Lieb V, Sikic D, Stohr R, Geppert C, Weyerer V, Bertz S, Kehlen A, Hartmann A, Wullich B, Taubert H, Wach S. CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage. Cancers (Basel). 2020;12(5). IF: 6,126
Achenbach F, Rose M, Ortiz-Bruchle N, Seillier L, Knuchel R, Weyerer V, Hartmann A, Morsch R, Maurer A, Ecke TH, Garczyk S, Gaisa NT. SWI/SNF Alterations in Squamous Bladder Cancers. Genes (Basel). 2020;11(11). IF: 2,984
Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M, Bridge Consortium G, Bridge Consortium G, Bridge Consortium G, Bridge Consortium G. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunol Res. 2019;7(6):923-38. IF: 8,728
Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiss CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2019;106:234-43. IF: 7,275
Bertz S, Eckstein M, Stoehr R, Weyerer V, Hartmann A. Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. Euro Urol Suppl. 2017:16/12:272-294. IF: 3,121

SCIENTIFIC CAREER

UNIVERSITY EDUCATION AND ACADEMIC DEGREES
2010 Start of studies of human medicine at Friedrich-Alexander University Erlangen-Nürnberg (FAU)
2012 1. State Examination/Physikum (Grade 1.0)
2017 2. State Examination (Grade 1.0)
2018 3. State Examination, human medicine (FAU) & Approbation (Grade 1.0)
08.10.2019 MD Thesis:” Immunohistochemical and molecular characteri-zation of early-onset bladder cancer patients“ at the Institute of Pathology, University Hospital Erlangen, Prof. Dr. A. Hartmann (magna cum laude)

PROFESSIONAL CAREER
01.02.2015-12.12.2015 Short-term research visit at the Spanish Cancer Centre in Madrid (CNIO) at Prof. Dr. F. Real and Prof. Dr. N. Malats
Since 2015 Member of the uropathology research group of the Institute of Pathology, University Hospital Erlangen (Head: Prof. Dr. A. Hartmann)
01.01.2018 Start of residency in surgical and molecular pathology, Institute of Pathology, University Hospital Erlangen (Director: Prof. Dr. A. Hartmann)
01.01.2018-31.12.2019 Basic residency in surgical and molecular pathology 01.01.2020-31.08.2023 Residency in surgical and molecular pathology
05.08.2022-07.08.2022 Maternity leave
Since 01.09.2023 Residency and MINT-Clinician Scientist in surgical and molecular
pathology, Institute of Pathology and Neuropathology, University Hospital Tübingen (Director: Prof. Dr. F. Fend)
Since 2023 Member of the Advanced Tissue Imaging & Digital Pathology group of the Institute of Pathology and Neuropathology, University Hospital Tübingen (Head: Prof. Dr. C. Schürch)

MAIN RESEARCH AREAS
- Identifying and understanding the tumorigenesis of histological and molecular subtypes of urothelial carcinomas
- Characterization of the immunological tumor microenvironment and its influence on cancer cells, correlations with clinico-pathological characteristics and

AWARDS
Mai 2022 Tertio loco – W1 junior professorship for Translational Oncology – Charité Berlin
February 2020 Roddy MacSween Price for a Pathologist in Training 2019 - Histopathology
March 2013 – December 2017 Scholarship holder of „Studienstiftung des Deutschen Volkes“
Februar 2015 – Oktober 2015 Scholarship holder of the Mildred-Scheel Doctoral Program of the German Cancer Aid
April 2013 Sophie-Wallner Price, University Hospital Erlangen
Oktober 2012 – März 2013 Scholarship holder of the „Deutschlandstipendium“

OTHER COMMITMENTS
Since 2018 Member of the German Society of Pathology
Since 2018 Member of the Bladder Cancer Initiative for Drug Consortium Germany
Since 2020 Member of the Genitourinary Pathology Society - GUPS
Since 2021 Junior Member of the International Academy of Pathology